Development of humanized microbiota mouse models of ME/CFS
Project Number1R21AI183042-01
Contact PI/Project LeaderLOMBARDI, VINCENT C
Awardee OrganizationUNIVERSITY OF NEVADA RENO
Description
Abstract Text
Project Summary/Abstract
Our preliminary data, as well as our previous published studies, show that ME/CFS cases have alterations in
gastrointestinal mucosal immunity and mitochondrial homeostasis. Several other studies have described
significant alterations in the composition of the gut microbiome in ME/CFS cases, when compared to age and
gender-matched controls, potentially implicating a pathological role for a dysbiotic microbiota in the progression
of ME/CFS through the gut-microbiota-brain axis. We hypothesize that by conducting a fecal microbiota
transplantation (FMT) with stool from ME/CFS cases into mice that are engrafted with a functional human
immune system, we can develop an animal model that will replicate ME/CFS-associated pathology. We further
hypothesize that this model can be used to conduct ME/CFS research that is not practical or possible when
working with human subjects.
In Specific Aim 1, we will characterize and transplant stool from ME/CFS cases and healthy controls into
common C57BL/6J laboratory mice, which have a normal murine immune system, as well as mice that are
engrafted with a functional human immune system. We will then evaluate these mice for exercise intolerance,
neurocognitive dysfunction, and sleep disturbances; behavioral alterations consistent with those observed in
human cases. In Aim 2, we will pathologically evaluate these mice to identify changes in the gut and the brain
that potentially implicate the altered microbiota in ME/CFS pathophysiology. These studies will lay the
foundation for a larger research focus to identify ways to target the gut-microbiota brain axis in the prevention
and treatment of ME/CFS.
ME/CFS is a multisystemic, debilitating, and neglected illness for which no accepted efficacious treatments are
currently available. Population-based epidemiologic studies suggest that ME/CFS may affect as many as 2.5
million people in the United States alone. Moreover, ME/CFS produces an annual economic burden of at least
$17 billion 4. Although ME/CFS represents a serious public health concern, after almost four decades of research,
the pathophysiology of this illness is still largely unknown.
Public Health Relevance Statement
Project Narrative
Several lines of evidence suggest that a gut-microbiota-brain axis connection is involved in the pathophysiology
of ME/CFS. Mice that received fecal transplants from human donors with other neuroimmune diseases present
with behavioral alterations consistent with these diseases, suggesting that fecal transplants may be used to create
humanized mouse models of ME/CFS. Therefore, we propose to develop humanized mouse models of ME/CFS
by using stool from ME/CFS subjects and healthy controls. Fecal transplants will be made using C57BL/6J mice
and Hu-CD34+ NSG-SGM3 transgenic mice engrafted with a human immune system. We will then evaluate
these mice for behavioral alterations and mucosal and neuroimmune alterations consistent with ME/CFS.
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
146515460
UEI
WLDGTNCFFJZ3
Project Start Date
07-May-2024
Project End Date
31-March-2026
Budget Start Date
07-May-2024
Budget End Date
31-March-2025
Project Funding Information for 2024
Total Funding
$218,850
Direct Costs
$150,000
Indirect Costs
$68,850
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Allergy and Infectious Diseases
$218,850
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1R21AI183042-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R21AI183042-01
Patents
No Patents information available for 1R21AI183042-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R21AI183042-01
Clinical Studies
No Clinical Studies information available for 1R21AI183042-01
News and More
Related News Releases
No news release information available for 1R21AI183042-01
History
No Historical information available for 1R21AI183042-01
Similar Projects
No Similar Projects information available for 1R21AI183042-01